- Case-Based Modules
- Initial Evaluation
- Dermatologic Manifestations
- Oral Manifestations
- OIs: Prophylaxis
- OIs: Treatment
- Antiretroviral Rx
- Antiretroviral Rx: Resistance
- Antiretroviral Rx: Adverse Effects
- Drug-Drug Interactions
- Postexposure Prophylaxis
- Perinatal Transmission
- Special Populations
- Prevention for Positives
- Challenging Unknowns
- Resource-Limited Settings
- Interactive Tutorials
- Routine HIV Screening
- Oraquick Advance Rapid HIV Test
- HIV Integration
- This program is funded through Health Resources and Services Administration, US Department of Health and Human Services.
Antiretroviral Rx
Question | Discussion | References | CME Credit
Case 2: Antiretroviral Regimens
You answered:
 |
Zidovudine-lamivudine (Combivir) plus efavirenz (Sustiva) |
|---|
This answer is incorrect. Although the regimen zidovudine-lamivudine plus efavirenz was previously a preferred and widely used regimen, the zidovudine-lamivudine component is no longer recommended as a preferred nucleoside reverse transcriptase inhibitor combination. The NNRTI efavirenz is considered a preferred medication when used with tenofovir-emtricitabine (Truvada).
Choose another answer:
Copyright © 2004-2013 University of Washington